Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Last trade$3.72
Day change+$0.01 (+0.27%)
Day range$3.72 – $3.85
Volume793,952
Market cap$283M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$283.38M
Price / earnings
—
Price / book
0.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.22×
Profitability
Earnings per share
-$1.00
Return on assets
-24.56%
Return on equity
-25.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
36.19×
Quick ratio
36.19×
Cash ratio
13.56×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FULC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$8.44M
$7.46M
$8.1M
$7.28M
$7.56M
$6.83M
$7M
$7.72M
Research and development
$3.03M
$12.44M
$14.08M
$15.42M
$14.3M
$12.99M
$13.4M
$11.71M
Total operating expenses
$13.86M
$29.31M
$22.19M
$22.69M
$21.86M
$19.82M
$20.4M
$19.43M
Operating income
-$13.86M
-$29.31M
-$22.19M
-$22.69M
-$21.86M
-$19.82M
-$20.4M
-$19.43M
Interest expense
$2.92M
$3.13M
$0
$0
$2.26M
$2.52M
$0
$0
Income before taxes
-$10.94M
-$26.18M
-$18.89M
-$20.33M
-$19.6M
-$17.3M
-$17.66M
-$16.57M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$10.94M
-$26.18M
-$18.89M
-$20.33M
-$19.6M
-$17.3M
-$17.66M
-$16.57M
Net income attributable to common shareholders
-$10.94M
-$26.18M
-$18.89M
-$20.33M
-$19.6M
-$17.3M
-$17.66M
-$16.57M
EBITDA
-$11.47M
-$19.69M
-$21.85M
-$22.35M
-$21.51M
-$19.47M
-$20.05M
-$19.06M
Basic earnings per share
-$0.14
-$0.34
-$0.25
-$0.31
-$0.31
-$0.28
-$0.28
-$0.27
Diluted earnings per share
-$0.14
-$0.34
-$0.25
-$0.31
-$0.31
-$0.28
-$0.28
-$0.28
Recent news
Company coverage with links to the original publishers.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.
Johnson Fistel is investigating Fulcrum Therapeutics for potential federal securities law violations following the company's June 1, 2026 announcement to discontinue its lead sickle cell drug pociredir due to FDA concerns about PRC2 complex targeting therapies carrying malignancy risks. The disclosure caused a sharp stock price decline, prompting the law firm to investigate potential investor losses and recovery options.
Fulcrum Therapeutics (NASDAQ: FULC) shares plunged 49.69% in after-hours trading after announcing the discontinuation of pociredir, its lead experimental drug for sickle cell disease, due to FDA concerns about cancer-related risks associated with PRC2 pathway targeting drugs. The company launched a strategic review process to explore merger, acquisition, or other alternatives to maximize shareholder value while preserving its $333.3 million in cash reserves.
Fulcrum Therapeutics reported positive clinical data for pociredir showing robust fetal hemoglobin induction and improvements in hemolysis markers in sickle cell disease patients. The company plans to initiate a registration-enabling trial in H2 2026 and ended Q1 with $333.3 million in cash, providing runway into 2029. CFO Alan Musso will retire later this year, and Dr. Josh Lehrer joined the board.
MedicAlert Foundation, the Sickle Cell Disease Association of America (SCDAA), and Fulcrum Therapeutics announced a three-year partnership to improve emergency department care for sickle cell disease patients. The collaboration provides participants with MedicAlert Smart Medical ID Cards linked to secure digital health profiles containing physician-approved pain plans and vital medical information accessible via QR code scanning, aiming to expedite care during acute pain crises.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.